[Non-alcoholic steatohepatitis with cirrhosis after raltitrexed administration].
Flamenbaum
M
M
Kemeny
J L
JL
Garcia
V
V
Artigue
F
F
Buffet
C
C
Cassan
P
P
D000230:Adenocarcinoma / Q000188:drug therapy; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D018450:Disease Progression; D016903:Drug Monitoring; D005218:Fat Necrosis; D005234:Fatty Liver / Q000139:chemically induced* / Q000378:metabolism; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000139:chemically induced* / Q000378:metabolism; D008111:Liver Function Tests; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects*; D012004:Rectal Neoplasms / Q000188:drug therapy; D013876:Thiophenes / Q000009:adverse effects*; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*
D000964:Antimetabolites, Antineoplastic; D011799:Quinazolines; D013876:Thiophenes; D013940:Thymidylate Synthase; C068874:raltitrexed